Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.
Health insurance claims database
Hip fracture
Nationwide study
Pharmacotherapy
Secondary fracture
Journal
Journal of bone and mineral metabolism
ISSN: 1435-5604
Titre abrégé: J Bone Miner Metab
Pays: Japan
ID NLM: 9436705
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
29
09
2022
accepted:
24
01
2023
pubmed:
1
3
2023
medline:
23
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
This study aimed to assess the association between pharmacotherapy and secondary hip fracture incidence. The correlation between secondary hip fracture incidence and the presence, type, and medication possession ratio (MPR) of pharmacotherapy was investigated using medical insurance data acquired from the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Data collected from female patients (n = 1,435,347) were analyzed. The 2-year secondary hip fracture incidence was 3.48% (n = 49,921). Secondary hip fracture was significantly more common in patients without medications (3.80%) than in those with medications (3.00%). Patients receiving selective estrogen receptor modulators (SERMs) had the lowest average age. The crude incidence of secondary hip fracture was the lowest in patients receiving SERMs (n = 2088 [2.52%]), followed by those taking bisphosphonates (n = 11,355 [2.88%]), denosumab (n = 1118 [2.90%]), no medications (n = 32,747 [3.80%]), and parathyroid hormone (PTH: n = 2163 [4.55%]), whereas the age-adjusted incidence was the lowest in patients administered denosumab (2.27%), followed by those taking bisphosphonates (2.47%), SERMs (2.55%), PTH (3.67%), and no medications (3.80%). The mean MPR was the highest in patients taking denosumab (64.9%), followed by those receiving bisphosphonates (58.7%), SERMs (58.2%), and PTH (40.6%) in the no hip fracture group. Secondary hip fractures were less likely to occur with medication versus no medication. Differences in the crude incidence of secondary hip fracture based on medications usage might be attributed to background characteristics.
Identifiants
pubmed: 36853423
doi: 10.1007/s00774-023-01411-4
pii: 10.1007/s00774-023-01411-4
doi:
Substances chimiques
Bone Density Conservation Agents
0
Denosumab
4EQZ6YO2HI
Selective Estrogen Receptor Modulators
0
Diphosphonates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
248-257Informations de copyright
© 2023. The Japanese Society Bone and Mineral Research.
Références
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739
doi: 10.1359/jbmr.2000.15.4.721
pubmed: 10780864
Frederiksen A, Abrahamsen B, Johansen PB, Sørensen HA (2018) Danish, national cross-sectional observational study on the prevalence of prior major osteoporotic fractures in adults presenting with hip fracture-limitations and scope for fracture liaison services in prevention of hip fracture. Osteoporos Int 29:109–114
doi: 10.1007/s00198-017-4247-1
pubmed: 28965215
Bynum JPW, Bell JE, Cantu RV, Wang Q, McDonough CM, Carmichael D, Tosteson TD, Tosteson ANA (2016) Second fractures among older adults in the year following hip, shoulder, or wrist fracture. Osteoporos Int 27:2207–2215
doi: 10.1007/s00198-016-3542-6
pubmed: 26911297
pmcid: 5008031
Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C; Fragility Fracture Network (FFN) Rehabilitation Research Special Interest Group (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 16:158
doi: 10.1186/s12877-016-0332-0
Papadimitriou N, Tsilidis KK, Orfanos P, Benetou V, Ntzani EE et al (2017) Burden of hip fracture using disability-adjusted life-years: a pooled analysis of prospective cohorts in the CHANCES consortium. Lancet Public Health 2:e239–e246
doi: 10.1016/S2468-2667(17)30046-4
pubmed: 29253489
Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, Lorentzon M, McCloskey EV, Harvey NC, Javaid MK, Kanis JA; International Osteoporosis Foundation (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59
doi: 10.1007/s11657-020-0706-y
Schemitsch E, Adachi JD, Brown JP, Tarride JE, Burke N, Oliveira T, Slatkovska L (2021) Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. Osteoporos Int 11:1–10
Saito T, Sterbenz JM, Malay S, Zhong L, MacEachern MP, Chung KC (2017) Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporos Int 28:3289–3300
doi: 10.1007/s00198-017-4175-0
pubmed: 28770272
Wang PW, Li YZ, Zhuang HF, Yu HM, Cai SQ, Xu H, Chen ZH, Lin JK, Yao XD (2019) Anti-osteoporosis medications associated with decreased mortality after hip fracture. Orthop Surg 11:777–783
doi: 10.1111/os.12517
pubmed: 31429532
pmcid: 6819189
Dobre R, Niculescu DA, Petca RC, Popescu RI, Petca A, Poiană C (2021) Adherence to anti-osteoporotic treatment and clinical implications after hip fracture: a systematic review. J Pers Med 11:341
doi: 10.3390/jpm11050341
pubmed: 33923261
pmcid: 8146075
Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247–257
doi: 10.1007/s00774-013-0447-8
Japan Osteoporosis Society (2015) Guidelines on the prevention and treatment of osteoporosis 2015. The committee for development of the guidelines on the prevention and treatment of osteoporosis. (in Japanese). http://www.josteo.com/ja/guideline/doc/15_1.pdf . Accessed 22 Sep 2022
Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M (2021) Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Arch Osteoporos 16:130
doi: 10.1007/s11657-021-00992-9
pubmed: 34510296
Chen YC, Lin WC (2017) Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures. Patient Prefer Adherence 11:839–843
doi: 10.2147/PPA.S131564
pubmed: 28490865
pmcid: 5414717
Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565–2573
doi: 10.1007/s00198-011-1668-0
pubmed: 21617992
Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M (2021) Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan. Arch Osteoporos 16:131
doi: 10.1007/s11657-021-00993-8
pubmed: 34515872
Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, Almasri J, Farah W, Sarigianni M, Muthusamy K, Al Nofal A, Haydour Q, Wang Z, Murad MH (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104:1623–1630
doi: 10.1210/jc.2019-00192
pubmed: 30907957
Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone 130:115081
doi: 10.1016/j.bone.2019.115081
pubmed: 31626995
Nakatoh S, Fujimori K, Ishii S, Tamaki J, Okimoto N, Ogawa S, Iki M (2022) Association of pharmacotherapy with the second hip fracture incidence in women: a retrospective analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Geriatr Gerontol Int 22:930–937
doi: 10.1111/ggi.14485
pubmed: 36167466
Ministry of Health, Labour, and Welfare (2020) The popularization and state of electronic receipt claims. https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000099002.pdf . (in Japanese) Accessed 22 Sep 2022
The Japanese Orthopaedic Association (2020) Results of National Survey of hip fracture in 2020. (in Japanese). https://www.joa.or.jp/member/committee/osteoporosis/pdf/femur20.pdf . Accessed 22 Sep 2022
Liu S, Zhu Y, Chen W, Sun T, Cheng J, Zhang Y (2015) Risk factors for the second contralateral hip fracture in elderly patients: a systematic review and meta-analysis. Clin Rehabil 29:285–294
doi: 10.1177/0269215514542358
pubmed: 25027445
Sheikh HQ, Hossain FS, Khan S, Usman M, Kapoor H, Aqil A (2019) Short-term risk factors for a second hip fracture in a UK population. Eur J Orthop Surg Traumatol 29:1055–1060
doi: 10.1007/s00590-019-02412-8
pubmed: 30864015
pmcid: 6570666
Conley RB, Adib G, Adler RA, Åkesson KE, Alexander IM et al (2020) Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res 35:36–52
doi: 10.1002/jbmr.3877
pubmed: 31538675
Barron RL, Oster G, Grauer A, Crittenden DB, Weycker D (2020) Determinants of imminent fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 31:2103–2111
doi: 10.1007/s00198-020-05294-3
pubmed: 32613410
pmcid: 7560920
Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29:2623–2637
doi: 10.1007/s00198-018-4759-3
pubmed: 30417253
van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102
doi: 10.1136/ard.2008.092775
pubmed: 18677009
Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780
doi: 10.1007/s00198-016-3868-0
pubmed: 28028554
Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgström F, McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporos Int 29:1747–1757
doi: 10.1007/s00198-018-4502-0
pubmed: 29947869
pmcid: 6076437